Bill Text: AZ SB1115 | 2018 | Fifty-third Legislature 2nd Regular | Introduced
Bill Title: Insurance coverage; abuse-deterrent opioids
Spectrum: Partisan Bill (Democrat 5-0)
Status: (Introduced - Dead) 2018-01-17 - Senate read second time [SB1115 Detail]
Download: Arizona-2018-SB1115-Introduced.html
|
REFERENCE TITLE: insurance coverage; abuse-deterrent opioids |
|
State of Arizona Senate Fifty-third Legislature Second Regular Session 2018
|
|
SB 1115 |
|
|
|
Introduced by Senators Bradley: Miranda, Otondo; Representatives Friese, Rios
|
AN ACT
Amending Title 20, chapter 4, article 3, Arizona Revised Statutes, by adding section 20‑826.05; amending Title 20, chapter 4, article 9, Arizona Revised Statutes, by adding section 20‑1057.18; amending Title 20, chapter 6, article 4, Arizona Revised Statutes, by adding section 20‑1342.07; Amending Title 20, chapter 6, article 5, Arizona Revised Statutes, by adding section 20‑1406.10; relating to prescription drug coverage.
(TEXT OF BILL BEGINS ON NEXT PAGE)
Be it enacted by the Legislature of the State of Arizona:
Section 1. Title 20, chapter 4, article 3, Arizona Revised Statutes, is amended by adding section 20-826.05, to read:
20-826.05. Abuse‑deterrent opioid analgesic drug products; coverage; definitions
A. A subscription contract that is issued to a subscriber in this state and that includes prescription drug benefits shall include coverage for the following:
1. At least two brand name abuse‑deterrent opioid analgesic drug products that each contain different analgesic ingredients and that are offered on the lowest cost tier for brand name prescription drugs on the corporation's prescription drug formulary.
2. If available, at least two generic abuse‑deterrent opioid analgesic drug products that each contain different analgesic ingredients and that are offered on the lowest cost tier for generic drugs on the corporation's prescription drug formulary.
B. A corporation may not require a subscriber to first use an opioid analgesic drug product without abuse‑deterrent labeling before providing coverage for an abuse‑deterrent opioid analgesic drug product that is covered on the corporation's prescription drug formulary.
C. Notwithstanding subsection B of this section, a corporation may undertake utilization review, including preauthorization, for an abuse‑deterrent opioid analgesic drug product that is covered by the corporation if the same utilization review requirements are applied to nonabuse‑deterrent opioid analgesic drug products that are covered by the corporation in the same formulary tier as the abuse‑deterrent opioid analgesic drug product.
D. For the purposes of this section:
1. "Abuse‑deterrent opioid analgesic drug product" means a brand name or generic opioid analgesic drug product that is approved by the United States food and drug administration with abuse‑deterrent labeling that indicates the drug product is expected to result in a meaningful reduction in abuse.
2. "Opioid analgesic drug product" means a drug product that contains an opioid agonist and that is indicated by the United States food and drug administration for the treatment of pain, regardless of whether the drug product either:
(a) Is in immediate release or extended release form.
(b) Contains other drug substances.
Sec. 2. Title 20, chapter 4, article 9, Arizona Revised Statutes, is amended by adding section 20-1057.18, to read:
20-1057.18. Abuse‑deterrent opioid analgesic drug products; coverage; definitions
A. An evidence of coverage that is issued to an enrollee in this state and that includes prescription drug benefits shall include coverage for the following:
1. At least two brand name abuse‑deterrent opioid analgesic drug products that each contain different analgesic ingredients and that are offered on the lowest cost tier for brand name prescription drugs on the health care services organization's prescription drug formulary.
2. If available, at least two generic abuse‑deterrent opioid analgesic drug products that each contain different analgesic ingredients and that are offered on the lowest cost tier for generic drugs on the health care services organization's prescription drug formulary.
B. A health care services organization may not require an enrollee to first use an opioid analgesic drug product without abuse‑deterrent labeling before providing coverage for an abuse‑deterrent opioid analgesic drug product that is covered on the health care services organization's prescription drug formulary.
C. Notwithstanding subsection B of this section, a health care services organization may undertake utilization review, including preauthorization, for an abuse‑deterrent opioid analgesic drug product that is covered by the health care services organization if the same utilization review requirements are applied to nonabuse‑deterrent opioid analgesic drug products that are covered by the health care services organization in the same formulary tier as the abuse‑deterrent opioid analgesic drug product.
D. For the purposes of this section:
1. "Abuse‑deterrent opioid analgesic drug product" means a brand name or generic opioid analgesic drug product that is approved by the United States food and drug administration with abuse‑deterrent labeling that indicates the drug product is expected to result in a meaningful reduction in abuse.
2. "Opioid analgesic drug product" means a drug product that contains an opioid agonist and that is indicated by the United States food and drug administration for the treatment of pain, regardless of whether the drug product either:
(a) Is in immediate release or extended release form.
(b) Contains other drug substances.
Sec. 3. Title 20, chapter 6, article 4, Arizona Revised Statutes, is amended by adding section 20-1342.07, to read:
20-1342.07. Abuse‑deterrent opioid analgesic drug products; coverage; definitions
A. A disability insurance policy that is issued to an insured in this state and that includes prescription drug benefits shall include coverage for the following:
1. At least two brand name abuse‑deterrent opioid analgesic drug products that each contain different analgesic ingredients and that are offered on the lowest cost tier for brand name prescription drugs on the disability insurer's prescription drug formulary.
2. If available, at least two generic abuse‑deterrent opioid analgesic drug products that each contain different analgesic ingredients and that are offered on the lowest cost tier for generic drugs on the disability insurer's prescription drug formulary.
B. A disability insurer may not require an insured to first use an opioid analgesic drug product without abuse‑deterrent labeling before providing coverage for an abuse‑deterrent opioid analgesic drug product that is covered on the disability insurer's prescription drug formulary.
C. Notwithstanding subsection B of this section, a disability insurer may undertake utilization review, including preauthorization, for an abuse‑deterrent opioid analgesic drug product that is covered by the disability insurer if the same utilization review requirements are applied to nonabuse‑deterrent opioid analgesic drug products that are covered by the disability insurer in the same formulary tier as the abuse‑deterrent opioid analgesic drug product.
D. For the purposes of this section:
1. "Abuse‑deterrent opioid analgesic drug product" means a brand name or generic opioid analgesic drug product that is approved by the United States food and drug administration with abuse‑deterrent labeling that indicates the drug product is expected to result in a meaningful reduction in abuse.
2. "Opioid analgesic drug product" means a drug product that contains an opioid agonist and that is indicated by the United States food and drug administration for the treatment of pain, regardless of whether the drug product either:
(a) Is in immediate release or extended release form.
(b) Contains other drug substances.
Sec. 4. Title 20, chapter 6, article 5, Arizona Revised Statutes, is amended by adding section 20-1406.10, to read:
20-1406.10. Abuse‑deterrent opioid analgesic drug products; coverage; definitions
A. A group or blanket disability insurance policy that is issued to an insured in this state and that includes prescription drug benefits shall include coverage for the following:
1. At least two brand name abuse‑deterrent opioid analgesic drug products that each contain different analgesic ingredients and that are offered on the lowest cost tier for brand name prescription drugs on the group or blanket disability insurer's prescription drug formulary.
2. If available, at least two generic abuse‑deterrent opioid analgesic drug products that each contain different analgesic ingredients and that are offered on the lowest cost tier for generic drugs on the group or blanket disability insurer's prescription drug formulary.
B. A group or blanket disability insurer may not require an insured to first use an opioid analgesic drug product without abuse‑deterrent labeling before providing coverage for an abuse‑deterrent opioid analgesic drug product that is covered on the group or blanket disability insurer's prescription drug formulary.
C. Notwithstanding subsection B of this section, a group or blanket disability insurer may undertake utilization review, including preauthorization, for an abuse‑deterrent opioid analgesic drug product that is covered by the group or blanket disability insurer if the same utilization review requirements are applied to nonabuse‑deterrent opioid analgesic drug products that are covered by the group or blanket disability insurer in the same formulary tier as the abuse‑deterrent opioid analgesic drug product.
D. For the purposes of this section:
1. "Abuse‑deterrent opioid analgesic drug product" means a brand name or generic opioid analgesic drug product that is approved by the United States food and drug administration with abuse‑deterrent labeling that indicates the drug product is expected to result in a meaningful reduction in abuse.
2. "Opioid analgesic drug product" means a drug product that contains an opioid agonist and that is indicated by the United States food and drug administration for the treatment of pain, regardless of whether the drug product either:
(a) Is in immediate release or extended release form.
